- Jazz zeroes in on next-gen T cell engagers with AbCellera deal<figure><div><img src="https://imgproxy.divecdn.com/-MQ-ipFDv1an0x5BAqQED_kVRHQW-j1q4uZZwHk8OOM/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9ISjBCNlQuanBn.webp"/></div></figur…BioPharma Dive · 1mo ago↗ source
- Jazz turns to AbCellera for T cell engagers in up to $4.1B partnershipFor much of its first decade, Canadian antibody developer AbCellera signed partnership after partnership, securing 40 biopharma alliances that led to more than a dozen clinical-stage drug candidate…Endpoints · 1mo ago↗ source
- Update: Spot Bio launches with $40M to study non-viral gene therapy for muscular dystrophyA startup with operations in California and China has quietly begun tests of a genetic medicine that could restore dystrophin, the vital muscle protein that is broken or missing in people born with…